AgaMatrix, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AgaMatrix, Inc. - overview
Established
2001
Location
Salem, NH, US
Primary Industry
Medical Devices & Equipment
About
AgaMatrix, Inc. specializes in innovative solutions for diabetes management, offering advanced glucose monitoring devices and mobile applications designed to improve user experience and health outcomes for individuals with diabetes. Founded in 2001 and headquartered in Salem, US, AgaMatrix, Inc. develops diabetes management technologies including glucose meters and test strips.
The company successfully raised USD 23. 00 mn in a Series C funding round led by Ferrer, Freeman & Co on October 5, 2017, totaling USD 23. 00 mn raised to date. The current valuation of the company stands at USD 202.
619 mn. Rick Valencia serves as the CEO. AgaMatrix focuses on innovative diabetes management solutions through a range of core products, including glucose meters, test strips, and mobile health applications. Their flagship product, the Jazz Wireless 2, employs WaveSense technology to provide clinically accurate blood glucose readings at affordable prices.
The Presto line of test strips offers additional affordable options for comprehensive diabetes management. These products cater to individuals managing diabetes, healthcare providers, and partners in the pharmaceutical and retail sectors, primarily available in North America, Europe, and select international markets. AgaMatrix generates revenue through direct-to-consumer sales of glucose monitoring devices and test strips, supplemented by partnerships with healthcare providers and distributors. Their business model includes retail sales where consumers purchase products such as the Jazz Wireless 2 and Presto test strips at pharmacies or online platforms.
The pricing reflects a commitment to affordability for both individual customers and bulk buyers, with potential collaborations with healthcare organizations to enhance their products' integration into broader diabetes care programs, expanding their market reach. AgaMatrix is focused on developing new diabetes management products and is exploring expansion into new geographic markets. The recent funding will support these initiatives and help the company enhance its product offerings and market presence. Specific details on upcoming product releases or targeted regions for expansion have not been disclosed.
Current Investors
incTank, Ferrer, Freeman & Co, Collaborative Seed and Growth Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Devices & Equipment
Website
www.agamatrix.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
AgaMatrix, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | AgaMatrix, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.